<table width="75%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13: Clinically Important Drug Interactions with INVEGA SUSTENNA<sup>®</sup>
</caption>
<col align="left" valign="top" width="18%"></col>
<col align="left" valign="top" width="82%"></col>
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Drugs with Potential for Inducing Orthostatic Hypotension</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Clinical Impact</td>
<td stylecode="Rrule">Because INVEGA SUSTENNA<sup>®</sup> has the potential for inducing orthostatic hypotension, an additive effect may occur when INVEGA SUSTENNA<sup>®</sup> is administered with other therapeutic agents that have this potential <content stylecode="italics">[see <linkhtml href="#S5.7">Warning and Precautions (5.7)</linkhtml>]</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Intervention</td>
<td stylecode="Rrule">Monitor orthostatic vital signs in patients who are vulnerable to hypotension <content stylecode="italics">[see <linkhtml href="#S5.7">Warnings and Precautions (5.7)</linkhtml>]</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Examples</td>
<td stylecode="Rrule">Nitrates<br/>Antihypertensive medicines: thiazide diuretics (e.g. hydrochlorothiazide); beta blockers (e.g. acebutolol); angiotensin-converting enzyme (ACE) inhibitors (e.g. lisinopril); angiotensin II receptor blockers (ARBs) (e.g. candesartan); calcium channel blockers (e.g. amlodipine); alpha-blockers (e.g. prazosin), alpha-agonists (e.g. clonidine), other diuretics (e.g. loop, K-sparing), vasodilators (e.g. hydralazine)</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Strong Inducers of CYP3A4 and P-gp</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Clinical Impact</td>
<td stylecode="Rrule">The concomitant use of paliperidone and strong inducers of CYP3A4 and P-gp may decrease the exposure of paliperidone <content stylecode="italics">[see <linkhtml href="#S12.3">Clinical Pharmacology (12.3)</linkhtml>]</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Intervention</td>
<td stylecode="Rrule">Avoid using CYP3A4 and/or P-gp inducers with INVEGA SUSTENNA<sup>®</sup> during the 1-month dosing interval, if possible. If administering a strong inducer is necessary, consider managing the patient using paliperidone extended release tablets <content stylecode="italics">[see <linkhtml href="#S2.5">Dosage and Administration (2.5)</linkhtml>]</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Examples</td>
<td stylecode="Rrule">Carbamazepine, rifampin, St John's Wort</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Lrule Rrule">
<content stylecode="bold">Dopamine Agonist</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Clinical Impact</td>
<td stylecode="Rrule">Paliperidone may antagonize the effect of levodopa and other dopamine agonist</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">  Intervention</td>
<td stylecode="Rrule">Monitor and manage patient as clinically appropriate</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">  Examples</td>
<td stylecode="Rrule">Levodopa, bromocriptine, ropinirole and pramipexole</td>
</tr>
</tbody>
</table>